Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia

European Heart Journal, Supplement

Volumn 18, Issue , 2016, Pages C2-C12

  Ferrari, Roberto ^a   Aguiar, Carlos ^b   Alegria, Eduardo ^c   Bonadonna, Riccardo C ^d   Cosentino, Francesco ^e   Elisaf, Moses ^f   Farnier, Michel ^g   Ferrières, Jean ^h   Filardi, Pasquale Perrone ⁱ   Hancu, Nicolae ^j   Kayikcioglu, Meral ^k   Mello E Silva, Alberto ^l,m   Millan, Jesus ⁿ   Reiner, Zeljko ^o   Tokgozoglu, Lale ^p   Valensi, Paul ^q   Viigimaa, Margus ^r   Vrablik, Michal ^s   Zambon, Alberto ^t   Zamorano, Jose Luis ^u   Catapano, Alberico L ^v   more..

^a UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^b HOSPITAL DE SANTA CRUZ   (Portugal)

^c Interventional Cardiology Department   (Spain)

^d UNIVERSITY OF PARMA   (Italy)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF IOANNINA   (Greece)

^g Lipid Clinic   (France)

^h UNIVERSITÉ DE TOULOUSE   (France)

ⁱ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^j IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^k EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^l HOSPITAL EGAS MONIZ   (Portugal)

^m NOVA MEDICAL SCHOOL   (Portugal)

ⁿ HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^o UNIVERSITY OF ZAGREB   (Croatia)

^p HACETTEPE UNIVERSITY   (Turkey)

^q UNIVERSITÉ PARIS 13   (France)

^r TALLINN UNIVERSITY OF TECHNOLOGY   (Estonia)

^s CHARLES UNIVERSITY   (Czech Republic)

^t UNIVERSITY OF PADOVA   (Italy)

^u UNIVERSITY OF ALCALÁ   (Spain)

^v UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

Atherogenic dyslipidaemia; Cardiovascular risk; Fenofibrate; Fenofibrate statin combination therapy; Residual cardiovascular risk; Statin

Indexed keywords

FENOFIBRATE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID;

ARTICLE; ATHEROGENESIS; ATHEROGENIC DYSLIPIDEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DYSLIPIDEMIA; HEART PROTECTION; HUMAN; LIFESTYLE; LIPID ANALYSIS; LONG TERM CARE; MEDICATION THERAPY MANAGEMENT; MONOTHERAPY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION;

EID: 84983080833     PISSN: 1520765X     EISSN: 15542815     Source Type: Journal    
DOI: 10.1093/eurheartj/suw009     Document Type: Article

References (56)

1. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372: 2387-2397.
2. Aguiar C, Alegria E, Bonadonna RC, Catapano AL, Cosentino F, Elisaf M, Farnier M, Ferrieres J, Filardi PP, Hancu N, Kayikcioglu M, Melloe Silva A, Millan J, Reiner Z, Tokgozoglu L, Valensi P, Viigimaa M, Vrablik M, Zambon A, Zamorano JL, Ferrari R.A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: a report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. Atheroscler Suppl 2015;19:1-12.
3. Fruchart JC, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, Barter P, Betteridge J, Bruckert E, Cuevas A, Farnier M, Ferrannini E, Fioretto P, Genest J, Ginsberg HN, Gotto AM Jr, Hu D, Kadowaki T, Kodama T, Krempf M, Matsuzawa Y, Nunez-Cortes JM, Monfil CC, Ogawa H, Plutzky J, Rader DJ, Sadikot S, Santos RD, Shlyakhto E, Sritara P, Sy R, Tall A, Tan CE, Tokgozoglu L, Toth PP, Valensi P, Wanner C, Zambon A, Zhu J, Zimmet P.Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol 2014;13:26.
4. Gitt AK, Drexel H, Feely J, Ferrieres J, Gonzalez-Juanatey JR, Thomsen KK, Leiter LA, Lundman P, da Silva PM, Pedersen T, Wood D, Junger C, Dellea PS, Sazonov V, Chazelle F, Kastelein JJ. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol 2012;19:221-230.
5. Leiter LA, Lundman P, da Silva PM, Drexel H, Junger C, Gitt AK. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med 2011;28:1343-1351.
6. Ayyobi AF, McGladdery SH, McNeely MJ, Austin MA, Motulsky AG, Brunzell JD. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2003;23: 1289-1294.
7. Onat A, Yazici M, Can G, Sniderman A. Evidence for a complex risk profile in obese postmenopausal Turkish women with hypertriglyceridaemia and elevated apolipoprotein B. Clin Sci (Lond) 2004;107:97-104.
8. Berneis K, Rizzo M, Hersberger M, Rini GB, Di Fede G, Pepe I, Spinas GA, Carmina E. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome. Int J Clin Pract 2009;63:56-62.
9. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-1818.
10. Varbo A, Benn M, Tybjærg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013;61:427-436.
11. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31:2844-2853.
12. Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, MaerzW, LehmacherW, Heibges A, Klingel R. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 2013;128:2567-2576.
13. Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, Mora S. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation 2014;129:635-642.
14. Albers JJ, Slee A, O'Brien KD, Robinson JG, Kashyap ML, Kwiterovich PO Jr, Xu P, Marcovina SM. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol 2013;62:1575-1579.
15. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native humancoronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation 1990;81: 470-476.
16. National Institute forHealth and Care Excellence (NICE). NICE guideline CG181. Cardiovascular disease: risk assessment and reduction, including lipid modification. http://www.nice.org.uk/guidance/cg181 (19 October 2015).
17. Ray KK, Kastelein JJ, Boekholdt SM, Nicholls SJ, Khaw KT, Ballantyne CM, Catapano AL, Reiner Z, Luscher TF. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 2014;35:960-968.
18. Giugliano R, Cannon C, Blazing M, Nicolau J, Corbalan R, Spinar J, Park J, White J, Braunwald E. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with vs without diabetes: the IMPROVE-IT Trial. 2015. no. 1947.
19. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2889-2934.
20. Ginsberg HN, Elam MB, Lovato LC, Crouse JR III, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574.
21. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjærg-Hansen A, Watts GF. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32:1345-1361.
22. Reiner Z. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr Metab Cardiovasc Dis 2013;23:799-807.
23. Perk J, De BG, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-1701.
24. Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002;30:1280-1287.
25. Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203-212.
26. Li C, Lin L, Zhang W, Zhou L, Wang H, Luo X, Luo H, Cai Y, Zeng C. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials. J Am Heart Assoc 2015;4:e001937.
27. Food andDrug Administration (FDA) Endocrinologicand Metabolic Drugs Advisory Committee. Trilipix (ACCORD) Advisory Committee Meeting. 19 May 2011.
28. Scott R, O'Brien R, Fulcher G, Pardy C, d'Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009;32: 493-498.
29. Hassan M.OSLER andODYSSEYLONGTERM: PCSK9 inhibitors on the right track of reducing cardiovascular events. Glob Cardiol Sci Pract 2015; 2015:20.
30. Degli Esposti L, Saragoni S, Batacchi P, Benemei S, Geppetti P, Sturani A, Buda S, Degli Esposti E. Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis. Clin Ther 2012;34:190-199.
31. Reiner Z. Combined therapy in the treatment of dyslipidemia. Fundam Clin Pharmacol 2010;24:19-28.
32. Kayikçioglu M, Ozerkan F, Soydan I. Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia. Am J Cardiol 1999;83:1135-1137, A9.
33. European Medicines Agency (EMA). Assessment report for fenofibrate, bezafibrate, ciprofibrate, and gemfibrozil containing medical products. EMA/CHMP/580013/2012.28 February 2011.
34. Jones PH, Davidson MH, Goldberg AC, Pepine CJ, Kelly MT, Buttler SM, Setze CM, Lele A, Sleep DJ, Stolzenbach JC. Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: pooled analysis of three phase 3, 12-week randomized, controlled studies. J Clin Lipidol 2009;3:125-137.
35. Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, Sleep DJ, Stolzenbach JC. Efficacy and safety of fenofibric acid co-administered with low-or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am J Cardiovasc Drugs 2010;10:73-84.
36. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgozoglu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, Marz W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015;36:1012-1022.
37. Hennekens CH, Kaski J. Secondary prevention of cardiovascular disease. http://www.uptodate.com/contents/secondary-preventionof-cardiovascular-disease#H1 (10 September 2015).
38. Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, DanchinN, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, De Backer G, Sirnes PA, Ezquerra EA, Avogaro A, Badimon L, Baranova E, Baumgartner H, Betteridge J, Ceriello A, Fagard R, Funck-Brentano C, Gulba DC, Hasdai D, Hoes AW, Kjekshus JK, Knuuti J, Kolh P, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Ponikowski P, Reiner Z, Sattar N, Schachinger V, Scheen A, Schirmer H, Stromberg A, Sudzhaeva S, Tamargo JL, Viigimaa M, Vlachopoulos C, Xuereb RG. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013;34:3035-3087.
39. Idzior-Walus B, Sieradzki J, Rostworowski W, Zdzienicka A, Kawalec E, Wojcik J, Zarnecki A, Blane G. Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest 2000;30:871-878.
40. Kraja AT, Province MA, Straka RJ, Ordovas JM, Borecki IB, Arnett DK. Fenofibrate and metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2010;10:138-148.
41. Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med 2010;363:692-694.
42. Koh EH, Kim MS, Park JY, Kim HS, Youn JY, Park HS, Youn JH, Lee KU. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation. Diabetes 2003;52:2331-2337.
43. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Choi IS, Shin EK. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005;45:1649-1653.
44. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-244.
45. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M. Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-1861.
46. Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D'Emden MC, Laakso M, Baker JR, Keech AC. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009;373: 1780-1788.
47. BGP Products Pty Ltd. Product Information Lipidilw. http://www.medicines.org.au/files/goplipid.pdf (10 September 2015).
48. Kostapanos MS, Florentin M, Elisaf MS. Fenofibrate and the kidney: an overview. Eur J Clin Invest 2013;43:522-531.
49. Mychaleckyj JC, Craven T, Nayak U, Buse J, Crouse JR, Elam M, Kirchner K, Lorber D, Marcovina S, Sivitz W, Sperl-Hillen J, Bonds DE, Ginsberg HN. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care 2012;35:1008-1014.
50. Foucher C, Brugere L, Ansquer JC. Fenofibrate, homocysteine and renal function. Curr Vasc Pharmacol 2010;8:589-603.
51. Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res 2015;102:63-70.
52. Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, Manolis AJ, Perez-Ruiz F, Mancia G. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens 2015;33:1729-1741.
53. Zentiva. Fenofibrate 267 mg capsules. Summary of product characteristics. http://www.medicines.org.uk/emc/medicine/22425/SPC (17 November 2015).
54. Verges B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia 2015;58:886-899.
55. Noonan JE, Jenkins AJ, Ma JX, Keech AC, Wang JJ, Lamoureux EL. An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes 2013;62:3968-3975.
56. McKeage K, Keating GM. Fenofibrate: a review of its use in dyslipidaemia. Drugs 2011;71:1917-1946.